Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcersxcess sugar intake
MISSISSAUGA, Canada I September 15, 2016 I Aralez Pharmaceuticals Inc.
New star-shaped polymers may spell end for antibiotics
Melbourne.
Sugar industry downplayed heart risks of sugar, promoted risks of fat: study
(Reuters Health) - In the 1960’s, before conflict of interest disclosure was required, the sugar industry sponsored research promoting dietary fat as an important cause of coronary heart dis...
Allergan to Buy Vitae Pharmaceuticals for $639 Million
Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals Inc.
Japan's Takeda prepares $15 billion for U.S. acquisitions - FT
TOKYO - Wed Sep 14, 2016 -- Takeda Pharmaceutical Co Ltd, Japan's leading drug maker, is ready to spend as much as $15 billion (11.
Bayer's Monsanto acquisition to face politically charged scrutiny
As the global agricultural sector races to consolidate, Bayer AG's $66 billion all-cash deal to acquire Monsanto Co will test growing political and consumer unease in the United States and abroad ...
Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes
SAN DIEGO, CA, USA I September 13, 2016 I Ligand Pharmaceuticals Incorporated (Nasdaq.
ChemDiv is presenting at the SCI's event: Innovation in Design, Supply and Acquisition for Compound Screening Libraries, on 14th September 2016 in Hatfield, UK
Dr.
Combination therapy with Glutaminyl Cyclase (QC) inhibitor PQ912 and pGlu-Abeta specific antibody PBD-C06 shows clear additive effects in reducing pGlu-Abeta as well as Abeta in Alzheimer-mouse model
HALLE (SAALE), Germany I September 13, 2016 I Probiodrug AG (Euronext Amsterdam.
Horizon Pharma Is Buying Raptor to Build Up Its Rare Disease Treatments
Horizon Pharma HZNP 0.
Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
REHOVOT, Israel and BRIDGEWATER, N.
Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek® 2016
REDWOOD CITY, CA, USA I September 9, 2016 I Heron Therapeutics, Inc.
579
580
581
582
583
584
585
586
587
